



ACGME International

**Advanced Specialty Program Requirements for
Graduate Medical Education in
Rheumatology
(Internal Medicine)**

Reformatted: 1 April 2022
Revised: 12 December 2015, Effective: 1 July 2016
Initial Approval: 2 October 2012

ACGME International Specialty Program Requirements for Graduate Medical Education in Rheumatology (Internal Medicine)

Int. Introduction

Background and Intent: Programs must achieve and maintain Foundational Accreditation according to the ACGME-I Foundational Requirements prior to receiving Advanced Specialty Accreditation. The Advanced Specialty Requirements noted below complement the ACGME-I Foundational Requirements. For each section, the Advanced Specialty Requirements should be considered together with the Foundational Requirements.

Int. I. Definition and Scope of the Specialty

Rheumatology is a subspecialty of internal medicine that~~The medical specialty of rheumatology focuses on the diagnosis and treatment therapy of conditions and medical diseases affecting of the joints, muscles, and connective tissues, bones~~
~~It deals mainly with clinical problems involving joints, soft tissues, certain autoimmune diseases, vasculitis, and heritable connective tissue disorders, and on processes of autoimmunity and inflammation that affect not only the musculoskeleton, but the organ systems more broadly.~~

Int. II. Duration of Education

Int. II.A. The educational program in rheumatology must be 24 or 36 months in length.

I. Institution

I.A. Sponsoring Institution

I.A.1. A fellowship in rheumatology must function as an integral part of an ACGME-I-accredited residency in internal medicine.

I.B. Participating Sites

See International Foundational Requirements, Section I.B.

II. Program Personnel and Resources

II.A. Program Director

See International Foundational Requirements, Section II.A.

II.B. Faculty

See International Foundational Requirements, Section II.B.

II.C. Other Program Personnel

II.C.1. Programs should have a working relationship with both a radiologist and an orthopaedic surgeon, including availability for teaching and

49		consultation.
50	II.C.2.	<u>Fellows should have meaningful working relationships, including</u>
51		<u>availability for teaching and consultation, with at least one pathologist,</u>
52		<u>one nephrologist, one dermatologist, one cardiologist, one radiologist,</u>
53		<u>and one orthopaedic surgeon;</u>
54		
55		
56	II.D.	Resources
57		
58	II.D.1.	The following laboratory and imaging services must be present at the
59		primary clinical site or at participating site(s):
60		
61	II.D.1.a)	clinical immunology lab services;
62		
63	II.D.1.b)	a compensated polarized light microscope;
64		
65	II.D.1.c)	computed tomography (CT), bone densitometry, magnetic
66		resonance imaging (MRI), musculoskeletal ultrasound, and
67		angiography; and,
68		
69	II.D.1.d)	ultrasound for both diagnostic and interventional musculoskeletal
70		applications at the bedside and in the ambulatory clinic.
71		
72	II.D.2.	Fellows must have access to facilities for rehabilitation medicine.
73		
74	II.D.3.	The program should have access to:
75		
76	II.D.3.a)	access to pathology services for evaluation of muscle, <u>nervous</u>
77		<u>system, skin, kidney,</u> vascular, and synovial biopsy materials;
78	II.D.3.b)	orthopaedic surgery services for obtaining synovial biopsies and
79		consultations for joint arthroplasty <u>and other surgical</u>
80		<u>treatments;and,</u>
81		
82	II.D.3.c)	other consultation services for obtaining indicated biopsies of
83		muscle, <u>nerveous system tissue,</u> skin, <u>kidneys,</u> and <u>arteries</u>
84		<u>vasculature.</u>
85		
86	III.	Fellow Appointment
87		
88	III.A.	Eligibility Criteria
89		
90	III.A.1.	Prior to appointment in the program, fellows should have completed an
91		ACGME-I-accredited residency program in internal medicine, or an
92		internal medicine residency program acceptable to the Sponsoring
93		Institution's Graduate Medical Education Committee.
94		
95	III.B.	Number of Fellows
96		
97		See International Foundational Requirements, Section III.B.
98		

99	IV. Specialty-Specific Educational Program	
100		
101	IV.A. ACGME-I Competencies	
102	IV.A.1.	The program must integrate the following ACGME-I Competencies into
103		the curriculum.
104		
105	IV.A.1.a)	Professionalism
106		
107	IV.A.1.a).(1)	Fellows must demonstrate a commitment to
108		professionalism and an adherence to ethical principles.
109		
110	IV.A.1.b)	Patient Care and Procedural Skills
111		
112	IV.A.1.b).(1)	Fellows must provide patient care that is compassionate,
113		appropriate, and effective for the treatment of health
114		problems and the promotion of health. Fellows must
115		demonstrate competence in managing the care of
116		patients:
117		
118	IV.A.1.b).(1).(a)	<u>in a variety of health care settings, including</u>
119		<u>inpatient and ambulatory settings; the practice</u>
120		<u>of health promotion, disease prevention,</u>
121		<u>diagnosis, care, and treatment of patients of</u>
122		<u>each gender, from adolescence to old age,</u>
123		<u>during health and all stages of illness;</u>
124	IV.A.1.b).(1).(b)	<u>using critical thinking and evidence-based tools;</u>
125	IV.A.1.b).(1).(c)	<u>using population-based data; and,</u>
126	IV.A.1.b).(1).(d)	<u>with whom they have limited or no physical contact,</u>
127		<u>through the use of telemedicine.</u>
128		
129	IV.A.1.b).(2).	<u>Fellows must demonstrate competence in the treatment of:</u>
130	IV.A.1.b).(2).(a).	<u>autoimmune manifestations of infectious conditions,</u>
131		<u>such as lyme disease, other tick- borne illness, and</u>
132		<u>subacute bacterial endocarditis;</u>
133		
134	IV.A.1.b).(2).(b).	crystal induced synovitis;
135	IV.A.1.b).(2).(c).	infection of joints and soft tissues;
136		
137	IV.A.1.b).(2).(d).	<u>inflammatory polymyositis (polymyositis,</u>
138		<u>dermatomyositis, necrotizing myositis, and inclusion</u>
139		<u>body myositis), as well as myositis mimics;</u>
140		
141	IV.A.1.b).(2).(e).	metabolic diseases of bone;
142	IV.A.1.b).(2).(f).	<u>monogenic and polygenic autoinflammatory</u>
143		<u>syndromes, including familial Mediterranean fever,</u>
144		<u>familial cold autoinflammatory syndromes, and others;</u>

145	IV.A.1.b).(2).(g).	musculoskeletal pain;
146		
147	IV.A.1.b).(2).(h).	non-articular rheumatic diseases, including
148		fibromyalgia;
149		
150	IV.A.1.b).(2).(i).	non-surgical exercise-related (sports) injury;
151		
152	IV.A.1.b).(2).(j).	osteoarthritis;
153		
154	IV.A.1.b).(2).(k).	osteoporosis;
155	IV.A.1.b).(2).(l).	<u>pediatric rheumatic diseases;</u>
156		
157	IV.A.1.b).(2).(m).	regional musculoskeletal pain syndromes, acute
158		and chronic musculoskeletal pain syndromes, and
159		exercise-related syndromes;
160	IV.A.1.b).(2).(n).	<u>relapsing polychondritis;</u>
161		
162	IV.A.1.b).(2).(o).	rheumatoid arthritis;
163		
164	IV.A.1.b).(2).(p).	Sjögren's Syndrome;
165		
166	IV.A.1.b).(2).(q).	spondyloarthropathies;
167		
168	IV.A.1.b).(2).(r).	systemic diseases with rheumatic manifestations;
169	IV.A.1.b).(2).(s).	systemic lupus erythematosus;
170		
171	IV.A.1.b).(2).(t).	scleroderma /systemic sclerosis <u>and scleroderma</u>
172		<u>mimics; and.</u>
173		
174	IV.A.1.b).(2).(u).	vasculitis, <u>including primary large, medium, and small</u>
175		<u>vessel vasculitis, vasculitis secondary to other</u>
176		<u>rheumatic diseases, and vasculitis mimics.</u>
177	<u>IV.A.1.b).(3).</u>	<u>Fellows must be able to perform all medical, diagnostic, and</u>
178		<u>surgical procedures considered essential to the subspecialty,</u>
179		<u>including;</u>
180	IV.A.1.b).(3).(a)	<u>performing diagnostic and therapeutic procedures</u>
181		<u>relevant to their individual specific planned career path,</u>
182		<u>to include:</u>
183	IV.A.1.b).(6).(a).(i)	performance of arthrocentesis of peripheral
184		joints and periarticular/soft tissue
185		injections, including instruction and
186		experience in performing these
187		procedures under ultrasound guidance;
188		and,
189		
190	IV.A.1.b).(3).(a).(i)	performance and interpretation of diagnostic
191		ultrasonography of painful musculoskeletal

192		structures commonly encountered in a
193		rheumatology clinic, including synovial joints,
194		periarticular soft tissues, tendons, and
195		ligaments.
196	IV.A.1.b).(3).(b)	<u>treating their patients' conditions with practices that are</u>
197		<u>patient-centered, safe, scientifically based, effective,</u>
198		<u>timely, and cost-effective, including musculoskeletal</u>
199		<u>pain assessment and management;</u>
200	IV.A.1. b).(3).(c)	<u>using diagnostic and/or imaging studies relevant to the</u>
201		<u>care of the patient, including:</u>
202		
203	IV.A.1.b).(3).(c).(i)	examination and interpretation of synovial
204		fluid under conventional and polarized light
205		microscopy; and,
206		
207	IV.A.1.b).(3).(c).(ii)	interpretation of radiographs of normal and
208		diseased joints, bones, periarticular
209		structures, and prosthetic joints.
210		
211	IV.A.1.c)	Medical Knowledge
212		
213	IV.A.1.c).(1)	Fellows must demonstrate knowledge of established and
214		evolving biomedical clinical, epidemiological, and social-
215		behavioral sciences, as well as the application of this
216		knowledge to patient care. Fellows must demonstrate
217		knowledge of:
218		
219	IV.A.1.c).(1).(a)	the scientific method of problem solving and
220		evidence-based decision-making;
221		
222	IV.A.1.c).(1).(b)	the indications, contraindications, and techniques
223		for, and limitations, complications, and interpretation
224		of results of those diagnostic and therapeutic
225		procedures integral to the discipline, including the
226		appropriate indications for and use of screening
227		tests and procedures, to include:
228	IV.A.1.c).(1).(b).(i)	arteriograms (conventional and MRI/
229		magnetic resonance angiogram (MRA)) for
230		patients with suspected or confirmed
231		vasculitis;
232	IV.A.1.c).(1).(b).(ii)	arthroscopy;
233		
234	IV.A.1.c).(1).(b).(iii)	biopsy specimens, including histochemistry
235		and immunofluorescence of tissues relevant to
236		the diagnosis of rheumatic diseases;
237		
238	IV.A.1.c).(1).(b).(iv)	bone densitometry;
239		
240	IV.A.1.c).(1).(b).(v)	CT of lungs and paranasal sinuses for

241		patients with suspected or confirmed
242		rheumatic disorders;
243	IV.A.1.c).(1).(b).(vi)	electromyograms and nerve conduction
244		studies for patients with suspected or
245		confirmed rheumatic disorders;
246		
247	IV.A.1.c).(1).(b).(vii)	<u>lip biopsy</u> , parotid scans, and salivary flow
248		studies;
249		
250	IV.A.1.c).(1).(b).(viii)	MRI of the central nervous system (brain
251		and spinal cord) for patients with suspected
252		or confirmed rheumatic disorders;
253		
254	IV.A.1.c).(1).(b).(ix)	plain radiography, arthrography,
255		ultrasonography, radionuclide scans, CT, and
256		MRI of joints, bones, and periarticular
257		structures;
258		
259	IV.A.1.c).(1).(b).(x)	Schirmer's <u>and rose Begal</u> tests; and,
260		
261	IV.A.1.c).(1).(b).(xi)	ultrasound scans of normal and painful
262		musculoskeletal structures commonly
263		encountered in a rheumatology clinic,
264		including synovial joints, periarticular soft
265		tissues, tendons, and ligaments.
266		
267	IV.A.1.c).(1).(c)	aging influences on musculoskeletal function and
268		responses to prescribed therapies for rheumatic
269		diseases;
270		
271	IV.A.1.c).(1).(d)	anatomy, basic immunology, genetic basis, cell
272		biology, and metabolism pertaining to rheumatic
273		diseases, disorders of connective tissue, metabolic
274		disease of bone, osteoporosis, and musculoskeletal
275		pain syndromes;
276		
277	IV.A.1.c).(1).(e)	appropriate employment of principles of physical
278		medicine and rehabilitation in the care of patients
279		with rheumatic disorders;
280	IV.A.1.c).(1).(f)	essential components of quality experimental
281		design, clinical trial design, data analysis, and
282		interpretation of results, and the importance of
283		adherence to ethical standards of experimentation;
284		
285	IV.A.1.c).(1).(g)	indications for surgical and orthopaedic
286		consultation, to include indications for arthroscopy
287		and joint replacement/arthroplasty ;
288		
289	IV.A.1.c).(1).(h)	pathogenesis, epidemiology, clinical expression,
290		treatments, and prognosis of the full range of
291		rheumatic and musculoskeletal diseases;

292		
293	IV.A.1.c).(1).(i)	pharmacokinetics, metabolism, adverse events,
294		interactions, and relative costs of drug therapies
295		used in the management of rheumatic disorders;
296		and,
297		
298	IV.A.1.c).(1).(j)	physical and biologic basis of the range of
299		diagnostic testing in rheumatology, and the
300		clinical test characteristics of these procedures.
301	<u>IV.A.1.c).(2).</u>	<u>Fellows must demonstrate sufficient knowledge specific to the</u>
302		<u>subspecialty of rheumatology including application of technology</u>
303		<u>appropriate for the clinical context, to include evolving</u>
304		<u>technologies.</u>
305		
306	IV.A.1.d)	Practice-Based Learning and Improvement
307		
308	IV.A.1.d).(1)	Fellows must demonstrate the ability to investigate and
309		evaluate their care of patients, to appraise and assimilate
310		scientific evidence, and to continuously improve patient
311		care based on constant self-evaluation and lifelong
312		learning.
313	IV.A.1.e)	Interpersonal and Communication Skills
314	IV.A.1.e).(1)	Fellows must demonstrate interpersonal and
315		communication skills that result in the effective exchange
316		of information and collaboration with patients, patients'
317		families, and health professionals.
318		
319	IV.A.1.f)	Systems-Based Practice
320		
321	IV.A.1.f).(1)	Fellows must demonstrate an awareness of and
322		responsiveness to the larger context and system of health
323		care, including the social determinates of health, as well as
324		the ability to call effectively on other resources in the
325		system to produce optimal care.
326		
327	IV.B.	Regularly Scheduled Educational Activities
328	IV.B.1.	<u>The educational program must include didactic instruction based on the</u>
329		<u>core knowledge content in rheumatology.</u>
330	IV.B.1.a)	<u>Fellows must have a sufficient number of didactic sessions to</u>
331		<u>ensure fellow-fellow and fellow-and-faculty member interaction.</u>
332	IV.B.2.	<u>The program must ensure that fellows have an opportunity to review all</u>
333		<u>knowledge content from conferences that they could not attend.</u>
334	IV.B.3.	<u>Fellows must receive instruction in practice management relevant to</u>
335		<u>rheumatology.</u>
336		
337	IV.C.	Clinical Experiences

338	IV.C.1.	<u>Assignment of rotations must be structured to minimize the frequency of</u>
339		<u>rotational transitions, and rotations must be of sufficient length to provide a</u>
340		<u>quality educational experience, defined by continuity of patient care, ongoing</u>
341		<u>supervision, longitudinal relationships with faculty members, and meaningful</u>
342		<u>assessment and feedback.</u>
343	IV.C.2.	<u>Rotations must be structured to allow fellows to function as a part of an</u>
344		<u>effective interprofessional team that works together toward the shared goals</u>
345		<u>of patient safety and quality improvement.</u>
346	IV.C.3.	<u>Rotations must be structured to minimize conflicting inpatient and outpatient</u>
347		<u>responsibilities.</u>
348		
349	IV.C.4.	At least 12 months of education must be devoted to clinical experience.
350		
351	IV.C.5.	Fellows must have experience in the role of a rheumatology consultant in
352		both the inpatient and ambulatory settings.
353	IV.C.6.	<u>The program must provide educational experiences in team-based care</u>
354		<u>that allow fellows to interact with and learn from other health care</u>
355		<u>professionals.</u>
356	IV.C.7.	<u>The educational program must provide fellows with elective experiences</u>
357		<u>relevant to their future practice or to further skill/competence development.</u>
358	IV.C.8.	Fellows must participate in training using simulation.
359	IV.C.9.	The program must include a minimum of two half-days of ambulatory care
360		per week, averaged throughout the educational program, including the
361		continuity ambulatory experience.
362		
363	IV.C.10.	Fellows should have a structured continuity ambulatory clinic experience
364		<u>for the duration of the program</u> that exposes them to the breadth and
365		depth of rheumatology.
366		
367	IV.C.10.a)	This experience should include an appropriate distribution of
368		patients of each gender and a diversity of ages.
369		
370	IV.C.10.a)	This experience should average one half-day each week,
371		averaged throughout the educational program.
372		
373	IV.C.10.a).(1)	Each fellow should, on average, be responsible for four to
374		eight patients during each half-day session.
375		
376	IV.C.10.a).(1).(a)	Each fellow should, on average, be responsible for
377		no more than eight to 12 patients during each half-
378		day ambulatory session.
379		
380	IV.C.7.a)	Continuity patients should not be limited to one disease type but
381		should expose fellows to a variety and multiples stages of
382		diseases.
383		
384	IV.C.10. b)	The continuing patient care experience should not be interrupted

385		by more than one month, excluding a fellow's vacation.
386		
387	IV.C.9.	Programs with the qualified faculty members and facilities should provide
388		education in pediatric rheumatic diseases.
389	IV.C.	Scholarly Activity
390		
391	IV.D.1.	Fellows' Scholarly Activity
392	IV.D.1.a)	<u>While in the program, each fellow must complete at least one of the</u>
393		<u>following scholarly activities: participation in grand rounds; poster</u>
394		<u>presentations; workshops; quality improvement presentations;</u>
395		<u>podium presentations; grant leadership; non-peer-reviewed</u>
396		<u>print/electronic resources; articles or publications; book chapters;</u>
397		<u>textbooks; webinars; service on professional committees; or service</u>
398		<u>as a journal reviewer, journal editorial board member, or editor.</u>
399	IV.D.2.	Faculty Scholarly Activity
400		
401		See International Foundational Requirements, Section IV.D.2.
402		
403	V.	Evaluation
404		
405		See International Foundational Requirements, Section V.
406		
407	VI.	The Learning and Working Environment
408	VI.A.	Principles
409		
410		See International Foundational Requirements, Section VI.A.
411		
412	VI.B.	Patient Safety
413		
414		See International Foundational Requirements, Section VI.B.
415		
416	VI.C.	Quality Improvement
417		
418		See International Foundational Requirements, Section VI.C.
419		
420	VI.D.	Supervision and Accountability
421		
422	VI.D.1.	Direct supervision of procedures performed by each fellow must occur
423		until competence has been acquired and documented by the program
424		director.
425		
426	VI.E.	Professionalism
427		
428		See International Foundational Requirements, Section VI.E.
429		
430	VI.F.	Well-Being
431		
432		See International Foundational Requirements, Section VI.F.
433		

434	VI.G.	Fatigue
435		
436		See International Foundational Requirements, Section VI.G.
437		
438	VI.H.	Transitions of Care
439		
440		See International Foundational Requirements, Section VI.H.
441		
442	VI.I.	Clinical Experience and Education
443		
444		See International Foundational Requirements, Section VI.I.
445		
446	VI.J.	On-Call Activities
447		
448		See International Foundational Requirements, Section VI.J.